Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc.; Wednesday December 10, 9:33 am EST
The company's studies showed that 78 percent of test mice, injected first with blood cells from humans vaccinated with HGP-30, then with large amounts of live AIDS virus, were protected from HIV infection, CEL-SCI said.
Of the mice receiving the non-vaccinated control blood, only 13 percent showed no evidence of infection, according to James Talmadge at the University of Nebraska Medical Center in Omaha, who performed the mouse study.
The study used Severe Combined ImmunoDeficient mice, who lack their own immune systems and therefore are considered by many scientists to be the best available animal model for HIV, CEL-SCI said.
Blood from human vaccinated volunteers was shown to have antibodies to HGP-30 that recognize HIV subtypes A, B, C and E, the company said, noting that those subtypes are the dominant strains in Africa, the U.S. and Europe and parts of Asia.
"These results provide evidence that HGP-30 may have worldwide applicability as an AIDS vaccine," said Prem Sarin, CEL-SCI's vice president of research, infectious disease, in a press statement.
971210
RE971216
Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .